Early in-hospital initiation of SGLT2 inhibitors in acute decompensated heart failure and after myocardial infarction: A narrative review
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular death and heart failure (HF) events across the whole spectrum of ejection fraction, and their benefit emerges within weeks of the first dose. This has moved the clinical question from whether to use them to when to start them. Hospitalization for a...